Research programme: CD26 antigen antagonists - Pfizer

Drug Profile

Research programme: CD26 antigen antagonists - Pfizer

Alternative Names: DP-893

Latest Information Update: 03 Aug 2009

Price : $50

At a glance

  • Originator Pfizer
  • Class Antihyperglycaemics; Pyrrolidines; Sulfonamides
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Type 2 diabetes mellitus

Most Recent Events

  • 03 Aug 2009 Preclinical development is ongoing in USA
  • 14 Jul 2006 A preclinical study has been added to the pharmacokinetics section
  • 06 Jul 2005 Preclinical trials in Type-2 diabetes mellitus in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top